

Publication Guidelines February 2020

As of October 2014 (with amendments in July 2018 and February 2020), authorship on CIMBA papers will change to the following:

CIMBA-only papers

On female carriers

- Writing Group members
- Core Group members (e.g. funders, genotypers, QC, analysis)
- plus one author per site that contributed DNA samples to the iCOGS/OncoArray experiments (regardless of the number of carriers they are contributing or how many pass QC),
- plus one *additional* author for 200-399 carriers, 2 for 400-599 carriers, 3 for 600-799 etc with no maximum
- for papers limited to *BRCA1* or *BRCA2* carriers, the numbers of authors will be calculated accordingly
- plus ‘on behalf of CIMBA’

On male carriers

- Writing Group members
- Core Group members (e.g. funders, genotypers, QC, analysis)
- plus one author per site that contributed DNA samples for OncoArray genotyping* (regardless of the number of carriers they are contributing or how many pass QC),
- plus one *additional* author for 10-19 carriers, 2 for 20-29 carriers etc with no maximum
- for papers limited to *BRCA1* or *BRCA2* carriers, the numbers of authors will be calculated accordingly
- plus ‘on behalf of CIMBA’

*For papers using phenotypes only, limit of two authors per site that contributes up to 100 male carriers, three for 101-399, four for 400 or more male carriers

On male *and* female carriers

- Each site will be entitled to the largest number of authors calculated on the basis of their male *and* female carriers
- plus writing group members and ‘on behalf of CIMBA’

In addition

For papers restricted to carriers of European ancestry

- Asian sites will be offered one authorship position

For papers restricted to carriers of Asian ancestry

- Numbers of authors per carriers for the Asian sites will be as above for male and female carriers

Similar rules would apply for descriptive papers, *i.e.* based on the number of mutation carriers contributed.

Note that the study name can count as an author, but cannot be included in addition to the author numbers described above.

Joint Consortium papers

Separate arrangements exist for joint consortium papers

For papers that include comprehensive analysis of CIMBA data

- Aim to be consistent with the arrangement made with the other consortia *e.g.* a maximum of two (or four, for the large CIMBA sites - CONSIT TEAM, EMBRACE, GC-HBOC, GEMO and **HEBON**) authors per site - but no more for any site than would be used on a CIMBA-only paper.

For papers with minimal reference to CIMBA results

- ‘CIMBA’ as an author, plus up to two people who did the analysis

Some flexibility should be allowed for in light of individual journal requirements regarding authorship. As in the Vancouver guidelines (<http://www.icmje.org/#author>), authorship credit should be based on

1. substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data
 2. drafting the article or revising it critically for important intellectual content and
 3. final approval of the version to be published. Authors should meet conditions 1, 2, and 3.
-

Publication guidelines 2005-2014

Authorship on CIMBA publications will be limited to members of the analytical/writing group plus a maximum of one named author per 92 eligible, carrier DNAs with all the necessary phenotypic data that are successfully genotyped. Group authorship (eg kConFab, EMBRACE) is encouraged, instead of a large number of named authors. “On behalf of CIMBA” will be added to the authorship if there are at least four participating groups. Some flexibility should be allowed for in light of individual journal requirements regarding authorship. As in the Vancouver guidelines (<http://www.icmje.org/#author>), authorship credit should be based on

1. substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data
2. drafting the article or revising it critically for important intellectual content and
3. final approval of the version to be published. Authors should meet conditions 1, 2, and 3.